Professor Jochen Seufert

University of Freiburg, Freiburg (Germany)

Follow

Contributor content

Increase in pulse rate with semaglutide did not result in increased adverse cardiac events in subjects with type 2 diabetes in the SUSTAIN 6 cardiovascular outcomes trial

Presentation

Increase in pulse rate with semaglutide did not result in increased adverse cardiac events in subjects with type 2 diabetes in the SUSTAIN 6 cardiovascular outcomes trial

ESC 365 is supported by

novartis

Explore sponsored resources